Search Result

Results for "

cholesterol excretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Akt (2) Apoptosis (2) Constitutive Androstane Receptor (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Metabolite (1) Endogenous Metabolite (9) Fluorescent Dye (1) FXR (5) Indoleamine 2,3-Dioxygenase (IDO) (2) LDLR (2) Mitochondrial Metabolism (2) NF-κB (2) p38 MAPK (2) Parasite (1) PI3K (2) Pregnane X Receptor (PXR) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) ROCK (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Endocrinology (3) Infection (1) Inflammation/Immunology (2) Metabolic Disease (18) Neurological Disease (2)

By Targets:

Acetyl-CoA Carboxylase (2)

Akt (2)

Apoptosis (2)

Constitutive Androstane Receptor (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Drug Metabolite (1)

Endogenous Metabolite (9)

Fluorescent Dye (1)

FXR (5)

Indoleamine 2,3-Dioxygenase (IDO) (2)

LDLR (2)

Mitochondrial Metabolism (2)

NF-κB (2)

p38 MAPK (2)

Parasite (1)

PI3K (2)

Pregnane X Receptor (PXR) (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (4)

ROCK (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (3)

Endocrinology (3)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (18)

Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dyes

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Acyltransferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0324

Cholic acid Maximum Cited Publications 20 Publications Verification	Endogenous Metabolite	Metabolic Disease
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-N0324S

Cholic acid-d4 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
Cholic acid-d₄ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N0324A

Cholic acid sodium Maximum Cited Publications 20 Publications Verification Sodium cholate	Endogenous Metabolite	Metabolic Disease
Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active .

HY-13995A

Sevelamer (hydrochloride) 1 Publications Verification	FXR	Metabolic Disease Endocrinology
Sevelamer hydrochloride is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer hydrochloride binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer hydrochloride binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer hydrochloride can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-13995B

Sevelamer carbonate 1 Publications Verification	FXR	Metabolic Disease Endocrinology
Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .

HY-N0430

Coptisine Coptisin	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0324S2

Cholic acid-13C	Endogenous Metabolite	Metabolic Disease
Cholic acid- ¹³C is the ¹³C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N0324R

Cholic acid (Standard) 15+ Cited Publications	Reference Standards Endogenous Metabolite	Metabolic Disease
Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-N0324S1

Cholic acid-d5	Endogenous Metabolite	Metabolic Disease
Cholic acid-d₅ is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.

HY-N0324F

Cholic acid-Biotin	Fluorescent Dye	Metabolic Disease
Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .

HY-13995

Sevelamer	FXR	Metabolic Disease Endocrinology
Sevelamer is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .

HY-N0324B

Cholic acid sodium hydrate	Endogenous Metabolite	Metabolic Disease
Cholic acid sodium hydrate is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. Cholic acid sodium hydrate facilitates fat absorption and cholesterol excretion. Cholic acid sodium hydrate is orally active .

HY-173033

MI-883	Pregnane X Receptor (PXR) Constitutive Androstane Receptor Cytochrome P450	Metabolic Disease
MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC₅₀=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC₅₀=0.1 μM). MI-883 stimulates CAR LBD assembly (EC₅₀=0.38 µM) and CAR3 variant activation (EC₅₀=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC₅₀=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N0324AR

Cholic acid sodium (Standard) Sodium cholate (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Cholic acid (sodium) (Standard) is the analytical standard of Cholic acid (sodium). This product is intended for research and analytical applications. Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active[1][2].

HY-101397R

Allopurinol riboside (Standard)	Reference Standards Parasite Drug Metabolite Endogenous Metabolite	Infection
Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .

HY-W343043

Pyrazinoylguanidine PZG	Drug Derivative	Cardiovascular Disease Metabolic Disease
Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .

Cholic acid-Biotin	Fluorescent Dyes
Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .

Cat. No.	Product Name	Category	Target	Chemical Structure